Next 10 |
2024-07-08 14:36:33 ET Summary Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 ...
2024-07-05 17:19:23 ET More on Inventiva Inventiva receives positive recommendation from DMC for late stage trial of NASH treatment Seeking Alpha’s Quant Rating on Inventiva Historical earnings data for Inventiva Financial information for Inventiva ...
2024-05-17 08:58:37 ET More on Inventiva Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva Phase 2 study for MASH drug meets primary endpoint Inventiva resumes Phase 3 stud...
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...
2024-03-28 11:27:08 ET Inventiva S.A. (IVA) Q4 2023 Results Conference Call March 28, 2024 08:00 AM ET Company Participants Frederic Cren - CEO Jean Volatier - CFO Conference Call Participants Seamus Fernandez - Guggenheim Securities Rami Katkhuda - L...
2024-03-27 16:06:34 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva Phase 2 study for MASH drug meets primary endpoint Inventiva resumes Phase 3 study for NASH drug, stock up 6% Seeking Alpha’s Qu...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
2024-03-19 08:44:21 ET More on Pre-market losers & stocks. Coinbase: My Pick For The Most Overvalued U.S. Stock Coinbase Global Inc (COIN) Morgan Stanley Technology, Media and Telecom Conference (Transcript) Coinbase: A Crypto Play With A Catalyst (Rating Upgrade...
2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...
News, Short Squeeze, Breakout and More Instantly...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...